盐酸吡格列酮胶囊联合缬沙坦胶囊治疗代谢综合征的临床研究

发布时间：2019-04-04 11:44

【摘要】：目的观察盐酸吡格列酮胶囊联合缬沙坦胶囊治疗代谢综合征的临床疗效及安全性。方法将48例代谢综合征患者随机分为对照组24例和试验组24例。对照组予以二甲双胍1.0 g,qd,口服+缬沙坦80 mg,qd,口服;试验组予以盐酸吡格列酮15 mg,qd,口服+缬沙坦80 mg,qd,口服。2组患者均治疗3个月。比较2组患者的临床疗效、收缩压(SBP)、舒张压(DBP)、血清中三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FPG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR),以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为91.67%(22/24例)和79.17%(19/24例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的SBP分别为(140.74±7.37)和(146.34±7.46)mm Hg,DBP分别为(89.58±4.36)和(96.37±4.86)mm Hg,TG分别为(1.65±0.23)和(2.05±0.29)mmol·L~(-1),LDL-C分别为(2.43±0.31)和(2.97±0.35)mmol·L~(-1),HDL-C分别为(1.74±0.22)和(1.31±0.11)mmol·L~(-1),FPG分别为(5.27±0.75)和(6.48±0.86)mmol·L~(-1),FINS分别为(6.73±0.89)和(8.05±1.12)pmol·L~(-1),HOMA-IR分别为(3.63±0.37)和(4.15±0.32),差异均有统计学意义(均P0.05)。试验组的药物不良反应主要有轻度颜面水肿、头痛,对照组的药物不良反应主要有消化道反应、头晕。试验组和对照组的药物不良反应发生率分别为8.33%和12.50%,差异无统计学意义(P0.05)。结论盐酸吡格列酮胶囊联合缬沙坦胶囊治疗代谢综合征的临床疗效确切,其能显著降低患者的血脂、血糖、血压水平,减轻胰岛素抵抗,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of pioglitazone hydrochloride capsule combined with valsartan capsule in the treatment of metabolic syndrome. Methods 48 patients with metabolic syndrome were randomly divided into control group (n = 24) and test group (n = 24). The control group was given metformin 1.0g, QD, oral valsartan 80 mg,qd, and pioglitazone hydrochloride 15 mg,qd, oral valsartan 80 mg,qd,. Both groups were treated with valsartan 80 mg,qd, for 3 months. The clinical effects of systolic blood pressure (SBP), diastolic blood pressure (DBP), triacylglycerol (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and fasting blood glucose (FPG), were compared between the two groups. Fasting insulin (FINS), insulin resistance index (HOMA-IR) and adverse drug reactions. Results after treatment, the total effective rate of treatment group and control group were 91.67% (22 / 24) and 79.17% (19 / 24) respectively, the difference was statistically significant (P0.05). After treatment, the SBP of test group and control group were (140.74 卤7.37) and (146.34 卤7.46) mm Hg,DBP, (89.58 卤4.36) and (96.37 卤4.86) mm Hg,), respectively. TG was (1.65 卤0.23) and (2.05 卤0.29) mmol 路L ~ (- 1), LDL-C was (2.43 卤0.31) and (2.97 卤0.35) mmol 路L ~ (- 1), respectively. HDL-C were (1.74 卤0.22) and (1.31 卤0.11) mmol 路L ~ (- 1), FPG were (5.27 卤0.75) and (6.48 卤0.86) mmol 路L ~ (- 1), respectively. FINS was (6.73 卤0.89) and (8.05 卤1.12) pmol 路L ~ (- 1), HOMA-IR was (3.63 卤0.37) and (4.15 卤0.32), respectively (P 0.05). The adverse drug reactions in the experimental group were mild facial edema and headache, while those in the control group were mainly alimentary tract reactions and dizziness. The incidence of adverse drug reactions in test group and control group was 8.33% and 12.50%, respectively, and there was no significant difference between the two groups (P0.05). Conclusion pioglitazone hydrochloride capsule combined with valsartan capsule is effective in the treatment of metabolic syndrome. It can significantly reduce the level of blood lipid, blood glucose and blood pressure, reduce insulin resistance, and does not increase the incidence of adverse drug reactions.
【作者单位】：南华大学附属第二医院心血管内科;
【基金】：国家医学教育发展中心医学研究课题基金资助项目(2010-24-03-009)
【分类号】：R589

【相似文献】